This is a working overview of albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-23 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Cases of stigmatism fall into two categories: self-inflicted wounds, which may be either cases of fraud or of unconscious self-infliction, and those that are caused by emotional states ... Self-induced (through autosuggestion) itching and subsequent scratching of which the individual is unaware is likely to occur in suggestible persons if the stimulus is a mental or actual picture of the Crucifixion used during meditation and if the main motive is to receive the stigmata. The motive behind that may be unconscious conflict and a desire to escape from an intolerable situation into invalidism where one's needs are taken care of. It then becomes a case of hysterical conversion reaction. Many cases of stigmatism can be explained as fraud or unconsciously self-inflicted wounds. In his Stigmata: A Medieval Phenomenon in a Modern Age, Ted Harrison suggests that there is no single mechanism whereby the marks of stigmata were produced. Harrison found no evidence from a study of contemporary cases that the marks were supernatural in origin. He concluded, however, that marks of natural origin need not be hoaxes. Some stigmatics marked themselves in attempt to suffer with Christ as a form of piety. Others marked themselves accidentally and their marks were noted as stigmata by witnesses. Often marks of human origin produced profound and genuine religious responses. Harrison also noted that after Saint Francis of Assisi, the stigmata was "seen as a predominantly female experience" with the female-to-male ratio of stigmatics being 7 to 1.
Early researchers found that an electric or magnetic field could split radioactive emissions into three types of beams. Ernest Rutherford named the three types alpha, beta, and gamma, in increasing order of their ability to penetrate matter. Alpha decay is observed only in heavier elements of atomic number 52 (tellurium) and greater, with the exception of beryllium-8 (which decays to two alpha particles). Gamma rays are emitted from excited states of nuclei as a side effect of alpha or beta decay. Beta decay is the only type to be observed in all the elements. Lead, atomic number 82, is the heaviest element to have any isotopes stable (to the limit of measurement) to radioactive decay. Radioactive decay is seen in all isotopes of all elements of atomic number 83 (bismuth) or greater. Bismuth-209, however, is only very slightly radioactive, with a half-life greater than the age of the universe by ten orders of magnitude; radioisotopes with extremely long half-lives are considered effectively stable for practical purposes. In analyzing the nature of the decay products, it was obvious from the direction of the electromagnetic forces applied to the radiations by external magnetic and electric fields that alpha particles carried a positive charge, beta particles carried a negative charge, and gamma rays were neutral. From the magnitude of deflection, it was clear that alpha particles were much more massive than beta particles.
== Medications == A variety of different sex-hormonal medications are used in feminizing hormone therapy for transgender women. These include estrogens to induce feminization and suppress testosterone levels; antiandrogens such as androgen receptor antagonists, antigonadotropins, GnRH modulators, and 5α-reductase inhibitors to further oppose the effects of androgens like testosterone; and progestogens for various possible though uncertain benefits. An estrogen in combination with an antiandrogen is the mainstay of feminizing hormone therapy for transgender women.
Sources: en.wikipedia.org
Accepted methods to detect and quantify the fluorescence wavelength shift include measuring the intensity at a single wavelength, computing a ratio of the intensity at two wavelengths (typically 330 nm and 350 nm), or calculating the barycentric mean (BCM) by measuring the center of mass of the fluorescence waveform. The latter BCM method takes advantage of the entire UV-fluorescence spectrum, thus allowing for flexibility when auto-fluorescent small molecules are present. Applications of nanoDSF include protein or antibody engineering, membrane protein research, quality control and formulation development, and ligand binding. NanoDSF has also been utilized to rapidly evaluate the melting points of enzyme libraries for biotechnological applications. Currently there are at least four instruments on the market that can measure fluorescence wavelength shifts in a high-throughput manner while heating the samples through a defined temperature ramp. These instruments employ either proprietary quartz capillaries, cartridges, or plates or generic high-throughput 384-well plastic plates for sample analysis.
== P == P42 MAP kinase -p53 - pancreatic polypeptide - parathyroid hormone receptor - partial pressure - passive transport - Pauling scale - PCR - peptide - peptide bond - peptide elongation factor - peptide elongation factor tu - peptide fragment - peptide initiation factor - peptide receptor - peptide termination factor - peripheral membrane protein - pesticide - pH - phage display - pharmaceutical - pharmacist - pharmacology - phenol - phenotype - phenyl group - phenylalanine - Philadelphia chromosome - phospholipid - phospholipid bilayer - phosphopeptide - phosphoprotein - phosphorus - phosphorylation - phosphoserine - phosphothreonine - phosphotyrosine - photobiology - photolysis - photophosphorylation - photoreceptor - photorespiration - photosynthesis - photosystem I - photosystem II - phototransduction - phylogenetics - phylogeny - physical chemistry - physiology - phytohaemagglutinin - pituitary hormone receptor - pituitary hormone-regulating hormone receptor - plant protein - plasma membrane - plasmid - plasmin - plasminogen - platelet glycoprotein GPIb-IX complex - platelet membrane glycoprotein - platelet-derived growth factor - platelet-derived growth factor receptor - polymer - polymerase chain reaction - polymerization - polymyxin - polymyxin B - polyomavirus transforming antigen - polypeptide - polysaccharide - porphyrin - Posttranslational modification - potassium - potassium channel - potential energy - pregnancy proteins - primary nutritional groups - primary structure - primer - prion - progesterone receptor - prokaryote - prolactin - prolactin receptor - proline - promoter - prostaglandin e receptor - prostaglandin receptor - protein - protein biosynthesis - Protein Data Bank - protein design - protein expression - protein folding - protein isoform - protein nuclear magnetic resonance spectroscopy - protein P16 - protein P34cdc2 - protein precursor - protein structure prediction - protein subunit - protein synthesis - protein targeting - protein translocation - protein-tyrosine kinase - protein-tyrosine-phosphatase - proteinoid - proteomics - protirelin - proto-oncogene - proto-oncogene proteins - proto-oncogene protein C-kit - proto-oncogene proteins c-abl - proto-oncogene proteins c-bcl-2 - Proto-oncogene proteins c-fos - proto-oncogene proteins c-jun - proto-oncogene proteins c-mo - proto-oncogene proteins c-myc - proto-oncogene proteins c-raf - proton - proton pump - protozoan proteins - purine - purinergic P1 receptor - purinergic P2 receptor - purinergic receptor - pyridine - pyrimidine - pyruvate - pyruvate oxidation
Dark chocolate, 70–85% cocoa solids: 80 mg Dark chocolate, 60–69% cocoa solids: 86 mg Dark chocolate, 45–59% cocoa solids: 43 mg Milk chocolate: 20 mg The stimulant effect of chocolate may be due to a combination of theobromine and theophylline, as well as caffeine.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.